# Trial Utilizing Metronidazole to Optimize the Microbiome of Rectal Adenocarcinoma Undergoing Neoadjuvant Therapy

> **NCT06569368** · PHASE2 · RECRUITING · sponsor: **M.D. Anderson Cancer Center** · enrollment: 60 (estimated)

## Conditions studied

- Rectal Adenocarcinoma

## Interventions

- **DRUG:** Metronidazole

## Key facts

- **NCT ID:** NCT06569368
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-07-10
- **Primary completion:** 2027-10-31
- **Final completion:** 2028-10-31
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2026-04-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06569368

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06569368, "Trial Utilizing Metronidazole to Optimize the Microbiome of Rectal Adenocarcinoma Undergoing Neoadjuvant Therapy". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT06569368. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*